Myo-Inositol Trispyrophosphate (ITPP) Capsules

Price range: $72.07 through $241.48

SKU: N/A Category:

Product Details – Myo-Inositol Trispyrophosphate (ITPP) 

Myo-Inositol Trispyrophosphate (ITPP) is a synthetic phosphorylated derivative of myo-inositol, a naturally occurring cyclohexanehexol. Structurally, ITPP is generated through the substitution of hydroxyl (-OH) groups with pyrophosphate moieties, resulting in a highly charged molecule with distinct biochemical properties.

ITPP is utilized in experimental and preclinical models to study oxygen transport dynamics, hemoglobin function, and cellular responses to hypoxic conditions. 

Mechanism of Action

ITPP interacts with hemoglobin within erythrocytes, modulating its oxygen-binding affinity. In research models, this interaction stabilizes the deoxygenated (T-state) conformation of hemoglobin, thereby shifting the oxygen dissociation curve and facilitating increased oxygen release under controlled conditions.

In preclinical models, ITPP is observed to penetrate red blood cells and alter intracellular biochemical conditions, influencing hemoglobin-oxygen equilibrium. This modulation provides a framework for studying oxygen transport efficiency, hypoxia-related signaling pathways, and cellular adaptation to reduced oxygen availability in experimental systems.

Properties

  • Molecular Formula: C6H12O21P6
  • Molecular Weight: 605.99 g/mol 
  • CAS Number: 802590-64-3
  • Synonyms: Myo-inositol trispyrophosphate, ITPP, 116EYZ0PPX, DTXCID301514847, DTXSID301029636

Research Applications

Applications in in vitro and experimental models include:

  • Investigation of hemoglobin oxygen-binding dynamics and dissociation kinetics
  • Study of oxygen delivery mechanisms at the cellular and molecular level
  • Analysis of hypoxia-inducible factor (HIF) pathway regulation under controlled oxygen conditions
  • Exploration of tumor microenvironment models with altered oxygen gradients in preclinical systems
  • Evaluation of erythrocyte-mediated oxygen transport in biochemical and physiological research models

Its ability to modulate hemoglobin-oxygen interactions makes ITPP a valuable compound for mechanistic studies involving oxygen availability and hypoxia-related signaling pathways.

Why Choose BehemothLabz to Buy Myo-Inositol Trispyrophosphate (ITPP)

Choose BehemothLabz for research-focused quality and consistency. Our Myo-Inositol Trispyrophosphate (ITPP) are manufactured to meet rigorous standards suitable for laboratory and experimental use.

Each batch undergoes third-party testing to verify purity, composition, and consistency. This ensures that researchers receive a product aligned with strict analytical requirements.

We offer secure ordering systems and reliable shipping options for both domestic and international customers. Our processes are designed to maintain confidentiality and protect customer data at every stage.

With BehemothLabz, you are selecting a product developed to support precision and reliability in research environments.

Disclaimer: This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments. 

References:

  • Gorgens, C., Guddat, S., Schanzer, W., & Thevis, M. (2014). Screening and confirmation of myo‐inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Drug Testing and Analysis, 6(11–12), 1102–1107. https://doi.org/10.1002/dta.1700
  • Krzykawska-Serda, M., Szczygiel, D., Gaweł, S., Drzal, A., Szczygiel, M., Kmieć, M. M., Mackiewicz, A., Kieda, C., & Elas, M. (2023). Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)–Local pO2 study in murine tumors. PLoS ONE, 18(5), e0285318. https://doi.org/10.1371/journal.pone.0285318
  • Sihn, G., Walter, T., Klein, J., Queguiner, I., Iwao, H., Nicolau, C., Lehn, J., Corvol, P., & Gasc, J. (2007). Anti‐angiogenic properties of myo‐inositol trispyrophosphate in ovo and growth reduction of implanted glioma. FEBS Letters, 581(5), 962–966. https://doi.org/10.1016/j.febslet.2007.01.079
Variant

100mg per capsule/60ct/6000mg, 100mg per capsule/30ct/3000mg, 50mg per capsule/60ct/3000mg, 50mg per capsule/30ct/1500mg